Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients With Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy
Brief Summary: Primary Objectives:

* To demonstrate the superiority of alirocumab in comparison with placebo in the reduction of calculated low-density lipoprotein cholesterol (LDL-C) in participants with diabetes treated with insulin and with hypercholesterolemia at high cardiovascular risk not adequately controlled on maximally tolerated LDL-C lowering therapy.
* To evaluate the safety and tolerability of alirocumab in participants with diabetes treated with insulin.

Secondary Objective:

To demonstrate that alirocumab was superior in comparison to placebo in its effects on other lipid parameters (i.e., measured LDL-C, non-high-density lipoprotein cholesterol \[non-HDL-C\], apolipoprotein B \[Apo B\], total cholesterol \[TC\], lipoprotein a \[Lp(a)\], high density lipoprotein cholesterol \[HDL-C\], triglyceride \[TG\] levels, triglyceride rich lipoproteins \[TGRL\], apolipoprotein A-1 \[Apo A-1\], apolipoprotein C-III \[Apo C-III\], and LDL particle number and size).


Options:
A: Arm Label: Bococizumab 150mg; Type: EXPERIMENTAL; Interventions: Biological: Bococizumab 150mg | Arm Label: Bococizumab 75mg; Type: EXPERIMENTAL; Interventions: Biological: Bococizumab 75mg | Arm Label: Bococizumab 150mg placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Bococizumab 150mg placebo | Arm Label: Bococizumab 75mg placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Bococizumab 75mg placebo | Intervention Type: BIOLOGICAL; Name: Bococizumab 150mg; Assigned to Arm(s): Bococizumab 150mg | Intervention Type: BIOLOGICAL; Name: Bococizumab 75mg; Assigned to Arm(s): Bococizumab 75mg | Intervention Type: BIOLOGICAL; Name: Bococizumab 150mg placebo; Assigned to Arm(s): Bococizumab 150mg placebo | Intervention Type: BIOLOGICAL; Name: Bococizumab 75mg placebo; Assigned to Arm(s): Bococizumab 75mg placebo
B: Arm Label: Alirocumab 75 mg Q2W/Up to 150 mg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Lipid-Modifying Therapy (LMT), Drug: Antihyperglycemic Drug | Arm Label: Placebo Q2W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Lipid-Modifying Therapy (LMT), Drug: Antihyperglycemic Drug | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Q2W | Intervention Type: DRUG; Name: Lipid-Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab 75 mg Q2W/Up to 150 mg Q2W, Placebo Q2W | Intervention Type: DRUG; Name: Antihyperglycemic Drug; Assigned to Arm(s): Alirocumab 75 mg Q2W/Up to 150 mg Q2W, Placebo Q2W
C: Arm Label: bococizumab (PF-04950615); Type: EXPERIMENTAL; Interventions: Drug: bococizumab (PF-04950615) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: bococizumab (PF-04950615); Assigned to Arm(s): bococizumab (PF-04950615) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Atorvastatin (statin rechallenge arm); Type: OTHER; Interventions: Drug: Atorvastatin, Drug: Placebo | Arm Label: Ezetimibe; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ezetimibe, Drug: Placebo | Arm Label: Alirocumab 75 mg/ up to 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Placebo | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin (statin rechallenge arm) | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 mg/ up to 150 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Alirocumab 75 mg/ up to 150 mg, Atorvastatin (statin rechallenge arm), Ezetimibe

Answer: B